Chdi Foundation, Inc.

Ucb Pharma, S.a.

Daniel Rees Allen

Alan Findlay Haughan

Roland W Bürli

Elizabeth Anne Saville-Stones

Celia Dominguez

Grant Wishart

Christopher A Luckhurst

Perla Breccia

Gilles Raphy

Ignacio Muñoz-Sanjuán

Rebecca E Jarvis

Stephen David Penrose

Samantha J Hughes

Andrew Sharpe

Andrew J Stott

Huw David Vater

Michael Wall

Michel C Maillard

Mizio Matteucci

Andrew Pate Owens

Jonathan David MacDonald

Graham John Warrellow

Julien Alistair Brown

Christopher Lowe

Verity Margaret Sabin

George Martin Buckley

Andrew James Ratcliffe

William Ross Pitt

Stephen Robert Mack

Christopher James Lock

Marianna Dilani Richard

Natasha Kinsella

Laura Jane Tait

David John Nash

Roland Burli

Sophie Caroline Williams

John Richard Davenport

Huw D Vater

Roland W BÛRLI

Ignacio Mun Oz-Sanjuan

Roland BÜRLI

Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use. 

Histone deacetylase inhibitors and compositions and methods of use thereof

Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use. 

Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use. The condition or disorder mediated by HDAC comprises a neurodegenerative pathology. Accordingly, also provided is a method of treating a neurodegenerative pathology mediated by HDAC in a subject in need of such a treatment, comprising administering to the subject a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt thereof, described herein. 

A series of substituted [1,3,5]triazin-2-yl derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

Triazine derivatives as kinase inhibitors

A series of quinoline derivatives, substituted by an optionally substituted bicyclic heteroaryl moiety consisting of two fused six-membered aromatic rings attached via an alkylene chain optionally linked to a heteroatom, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

Quinoline derivatives as kinase inhibitors

A series of amino-substituted fused pyridine and pyrazine derivatives, in particular amino-substituted quinoline and quinoxaline derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

Fused pyridine and pyrazine derivatives as kinase inhibitors

A series of heteroaryl-substituted quinoxaline and quinoline derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions, said substituted derivatives having the general formula 

Quinoxaline and quinoline derivatives as kinase inhibitors

Growing community of inventors

Saffron Walden, United Kingdom

Daniel Rees Allen